tirzepatide news update Explained: The Future of Weight Management FDA declares Mounjaro, Zepbound shortage

"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial." Lancet , 398(10295), 143-155

Step Therapy: Some insurance plans require you to try other, less expensive weight loss medications before considering Zepbound

21 Furthermore, obesity contributes to imbalanced body metabolism and chronic inflammatory states through the secretion of adipokines

Can Tirzepatide cause diarrhea? - This is a most often question of patients

Many patients begin to notice significant improvements in their weight and appetite control after just a few weeks

Is Tirzepatide still a good option for weight loss